52
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Bivalirudin plus loading dose of cilostazol-based triple-antiplatelet in treatment of non-ST-elevation myocardial infarction following percutaneous coronary intervention

, , , , , , , , & show all
Pages 1469-1473 | Published online: 28 Sep 2015

References

  • StoneGWWitzenbichlerBGuagliumiGBivalirudin during Primary PCI in Acute Myocardial InfarctionN Engl J Med20083582218223018499566
  • YagiHYamaguchiNShidaYCilostazol down-regulates the height of mural platelet thrombi formed under a high-shear rate flow in the absence of ADAMTS13 activityEur J Pharmacol20126911–315115522796451
  • MeadowsTABhattDLClinical aspects of platelet inhibitors and thrombus formationCirc Res20071001261127517495233
  • ChenKYRhaSWLiYJTriple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary interventionCirculation20091193207321419528339
  • LeeSWChunKJParkSWComparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials)Am J Cardiol201010516817320102913
  • No authors listedThe Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study GroupN Engl J Med19853129329364038784
  • ZhaoYJFuXHMaXXIntracoronary fixed dose of nitroprus-side via thrombus aspiration catheter for the prevention of the no-reflow phenomenon following primary percutaneous coronary intervention in acute myocardial infarctionExp Ther Med2013647948424137212
  • BologneseLFalsiniGLiistroFRandomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trialJ Am Coll Cardiol20064752252816458130
  • KastratiANeumannFJMehilliJBivalirudin versus unfractionated heparin during percutaneous coronary interventionN Engl J Med200835968869618703471
  • StoneGWWareJHBertrandMEAntithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trialJAMA20072982497250618056903
  • KimISJeongYHParkYInteraction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) studyBr J Clin Pharmacol20127362964022007612
  • ShimCYYoonSJParkSThe clopidogrel resistance can be attenuated with triple antiplatelet therapy in patients undergoing drug-eluting stents implantationInt J Cardiol200913435135518579227
  • JeongYHLeeSWChoiBRRandomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized studyJ Am Coll Cardiol2009531101110919324253
  • HolmesMVPerelPShahTHingoraniADCasasJPCYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysisJAMA20113062704271422203539
  • ZhouHFengXLZhangHYXuFFZhuJTriple versus dual anti-platelet therapy for coronary heart disease patients undergoing percutaneous coronary intervention: A meta-analysisExp Ther Med2013641034104024137311
  • LeeBKLeeSWParkSWEffects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantationAm J Cardiol200710061061417697815
  • PriceMJEndemannSGollapudiRRPrognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantationEur Heart J200829992100018263931
  • HanYLiYWangSCilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled studyAm Heart J200915773373919332203
  • KimBKOhSJYoonSJJeonDWKoYGYangJYA randomized study assessing the effects of pretreatment with cilostazol on periprocedural myonecrosis after percutaneous coronary interventionYonsei Med J201152571772621786434
  • JinEZYuLHLiXQLoading effect of 200 mg cilostazol on platelte inhibition in patients undergoing percutaneous coronary interventionInt Heart J2012531422398668
  • SantulliGWronskaAUryuKA selective microRNA-based strategy inhibits restenosis while preserving endothelial functionJ Clin Invest20141244102411425133430